Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial.

Background: Few treatments are available for individuals with marked treatment-resistant depression (TRD).

Objective: Evaluate the safety and effectiveness of FDA-approved adjunctive vagus nerve stimulation (VNS) in patients with marked TRD.

Methods: This 12-month, multicenter, double-blind, sham-controlled trial included 493 adults with marked treatment-resistant major depression who were randomized to active or no-stimulation sham VNS for 12 months.

Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial.

Background: Depression treatments aim to minimize symptom burden and optimize quality of life (QoL) and psychosocial function.

Objective: Compare the effects of adjunctive versus sham vagus nerve stimulation (VNS) on QoL and function in markedly treatment-resistant depression (TRD).

Methods: In this multicenter, double-blind, sham-controlled trial, 493 adults with TRD and ≥4 adequate but unsuccessful antidepressant treatment trials (current episode) were randomized to active (n = 249) or sham (n = 244) VNS (plus treatment as usual) over a 12-month observation period.

Who are the Parents? Risk and Resiliency Among Parents of Youth Receiving Intensive Home-Based Psychiatric Treatment.

Despite their explicit focus on family functioning and mounting evidence of the intergenerational mechanisms of childhood experiences (Zhang et al., 2022), very little is known about the parents of the high-risk youth receiving Intensive Home-Based Treatment (IHBT). Knowledge about parents' childhood experiences of risk and resilience, which are known to impact parenting behaviors, may provide insight into the complex clinical presentations frequently seen in this population and help guide the implementation of maximally effective interventions.

Cognitive benefits of folic acid supplementation during pregnancy track with epigenetic changes at an imprint regulator.

Background: The human ZFP57 gene is a major regulator of imprinted genes, maintaining DNA methylation marks that distinguish parent-of-origin-specific alleles. DNA methylation of the gene itself has shown sensitivity to environmental stimuli, particularly folate status. However, the role of DNA methylation in ZFP57's own regulation has not been fully investigated.